A recent article published on the Journal of Managed Care Pharmacy (JMCP) outlines what impact value-based insurance design (VBID) can have on costs and patient populations.
Some stakeholders see VBID as a way to “obtain better value for money,” the author writes, but a lack of a clear definition of “value” remains one key issue that stakeholders must overcome.
“Among high-income countries, the United States is a clear outlier in drug spending and population health — a fact that confronts stakeholders with the question of how to obtain better value for money,” the author writes. “Looking forward, the work of managed care stakeholders is to rigorously and explicitly define ‘value’ and to look for novel ways to apply value to VBID.”
To read the full article on JMCP, click here.